ConvaTec Group - CTEC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 259
  • Forecasted Upside: 25.97 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
GBX 205.60
▲ +4.8 (2.39%)

This chart shows the closing price for CTEC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ConvaTec Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CTEC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CTEC

Analyst Price Target is GBX 259
▲ +25.97% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for ConvaTec Group in the last 3 months. The average price target is GBX 259, with a high forecast of GBX 295 and a low forecast of GBX 210. The average price target represents a 25.97% upside from the last price of GBX 205.60.

This chart shows the closing price for CTEC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in ConvaTec Group. This rating has held steady since July 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 2 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
7/9/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
10/7/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
1/5/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
4/5/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
7/4/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/2/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/2/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/8/2022Berenberg BankBoost TargetBuyGBX 250 ➝ GBX 280
8/11/2022Royal Bank of CanadaReiterated RatingSector PerformGBX 210
8/5/2022JPMorgan Chase & Co.Boost TargetOverweightGBX 255 ➝ GBX 275
8/5/2022BarclaysBoost TargetOverweightGBX 285 ➝ GBX 295
7/4/2022BarclaysReiterated RatingOverweightGBX 285
6/27/2022JPMorgan Chase & Co.Boost TargetOverweightGBX 230 ➝ GBX 255
5/31/2022BarclaysLower TargetOverweightGBX 290 ➝ GBX 285
5/18/2022JPMorgan Chase & Co.Reiterated RatingOverweightGBX 230
5/18/2022Berenberg BankReiterated RatingBuyGBX 250
5/18/2022Royal Bank of CanadaUpgradeSector PerformGBX 195 ➝ GBX 210
4/13/2022Berenberg BankReiterated RatingBuyGBX 250
3/24/2022Royal Bank of CanadaReiterated RatingUnderperformGBX 195
3/23/2022Berenberg BankReiterated RatingBuyGBX 250
3/16/2022Berenberg BankInitiated CoverageBuyGBX 250
3/8/2022BarclaysLower TargetOverweightGBX 295 ➝ GBX 290
2/4/2022Royal Bank of CanadaReiterated RatingUnderperformGBX 195
1/4/2022JPMorgan Chase & Co.Reiterated RatingOverweight
11/24/2021Royal Bank of CanadaLower TargetUnderperformGBX 213 ➝ GBX 195
11/1/2021CitigroupReiterated RatingNeutralGBX 235
11/1/2021JPMorgan Chase & Co.Boost TargetOverweightGBX 272 ➝ GBX 278
11/1/2021BarclaysBoost TargetOverweightGBX 275 ➝ GBX 290
10/29/2021Shore CapitalReiterated RatingBuy
9/9/2021JPMorgan Chase & Co.UpgradeOverweightGBX 229 ➝ GBX 272
8/10/2021Shore CapitalReiterated RatingBuy
8/9/2021Royal Bank of CanadaDowngradeUnderperformGBX 230 ➝ GBX 213
8/2/2021Credit Suisse GroupBoost TargetUnderperformGBX 200 ➝ GBX 215
8/2/2021JPMorgan Chase & Co.Boost TargetNeutralGBX 212 ➝ GBX 229
7/30/2021Shore CapitalReiterated RatingBuy
6/23/2021Numis SecuritiesReiterated RatingBuyGBX 310
6/1/2021Royal Bank of CanadaBoost TargetSector PerformGBX 200 ➝ GBX 230
5/11/2021Shore CapitalReiterated RatingBuy
4/29/2021Shore CapitalReiterated RatingBuy
3/11/2021Shore CapitalReiterated RatingBuy
11/2/2020Shore CapitalReiterated RatingHold
10/29/2020Credit Suisse GroupBoost TargetUnderperformGBX 185 ➝ GBX 190
10/29/2020JPMorgan Chase & Co.Boost TargetUnderweightGBX 175 ➝ GBX 176
9/29/2020Royal Bank of CanadaDowngradeSector PerformGBX 245 ➝ GBX 200
7/22/2020BarclaysReiterated RatingEqual weight
7/8/2020BarclaysReiterated RatingEqual weight
7/2/2020Morgan StanleyBoost TargetEqual weightGBX 206 ➝ GBX 208
7/2/2020Peel HuntReiterated RatingAdd
6/30/2020JPMorgan Chase & Co.Boost TargetUnderweightGBX 167 ➝ GBX 172
6/26/2020Peel HuntDowngradeAddGBX 220 ➝ GBX 225
6/18/2020CitigroupReiterated RatingNeutral
6/10/2020Royal Bank of CanadaUpgradeOutperformGBX 178 ➝ GBX 245
6/3/2020Peel HuntReiterated RatingBuy
5/20/2020Jefferies Financial GroupLower TargetBuyGBX 250 ➝ GBX 240
5/18/2020BarclaysBoost TargetEqual WeightGBX 182 ➝ GBX 190
5/1/2020CSFBBoost TargetUnderperformGBX 175 ➝ GBX 180
5/1/2020JPMorgan Chase & Co.Boost TargetUnderweightGBX 160 ➝ GBX 167
5/1/2020Credit Suisse GroupBoost TargetUnderperformGBX 175 ➝ GBX 180
5/1/2020UBS GroupBoost TargetBuyGBX 235 ➝ GBX 245
4/30/2020Shore CapitalReiterated RatingHold
4/30/2020Peel HuntReiterated RatingBuy
4/24/2020Peel HuntReiterated RatingBuy
4/7/2020Peel HuntReiterated RatingBuy
4/1/2020JPMorgan Chase & Co.Lower TargetUnderweightGBX 177 ➝ GBX 160
3/30/2020Peel HuntReiterated RatingBuy
3/20/2020Royal Bank of CanadaLower TargetSector PerformerGBX 197 ➝ GBX 178
3/19/2020Peel HuntReiterated RatingBuy
3/12/2020Peel HuntLower TargetBuyGBX 250 ➝ GBX 220
3/5/2020Peel HuntReiterated RatingBuy
3/2/2020UBS GroupReiterated RatingBuy
3/2/2020JPMorgan Chase & Co.Boost TargetUnderweightGBX 168 ➝ GBX 177
2/24/2020Peel HuntReiterated RatingBuy
2/21/2020UBS GroupReiterated RatingBuy
2/18/2020BarclaysLower TargetEqual weightGBX 185 ➝ GBX 182
2/13/2020Peel HuntReiterated RatingBuy
2/5/2020Peel HuntReiterated RatingBuy
2/4/2020JPMorgan Chase & Co.Reiterated RatingUnderweightGBX 168
2/3/2020BarclaysReiterated RatingEqual weight
1/27/2020Peel HuntReiterated RatingBuy
1/23/2020Shore CapitalDowngradeHold
1/21/2020Jefferies Financial GroupBoost TargetBuyGBX 220 ➝ GBX 250
1/20/2020JPMorgan Chase & Co.DowngradeUnderweightGBX 171 ➝ GBX 168
1/10/2020UBS GroupUpgradeBuyGBX 185 ➝ GBX 235
1/7/2020Peel HuntReiterated RatingBuy
1/7/2020BarclaysReiterated RatingEqual weight
12/9/2019Royal Bank of CanadaDowngradeSector PerformerGBX 210 ➝ GBX 197
12/5/2019Peel HuntReiterated RatingBuy
11/29/2019Jefferies Financial GroupBoost TargetBuyGBX 145 ➝ GBX 220
11/22/2019Shore CapitalReiterated RatingBuy
11/4/2019Peel HuntReiterated RatingBuy
11/1/2019BarclaysBoost TargetEqual weightGBX 130 ➝ GBX 185
10/31/2019JPMorgan Chase & Co.Reiterated RatingNeutralGBX 174 ➝ GBX 171
10/30/2019The Goldman Sachs GroupBoost TargetNeutralGBX 118 ➝ GBX 183
10/28/2019UBS GroupReiterated RatingNeutral
10/25/2019Peel HuntReiterated RatingBuyGBX 280
10/25/2019Peel HuntReiterated RatingBuyGBX 280
10/17/2019Credit Suisse GroupDowngradeUnderperform
10/7/2019Peel HuntReiterated RatingBuy
9/18/2019Peel HuntReiterated RatingBuyGBX 280
9/18/2019Peel HuntReiterated RatingBuyGBX 280
9/2/2019Peel HuntReiterated RatingBuy
8/19/2019Peel HuntReiterated RatingBuy
8/12/2019Peel HuntBoost TargetBuyGBX 230 ➝ GBX 280
8/6/2019UBS GroupBoost TargetNeutralGBX 129 ➝ GBX 185
8/5/2019JPMorgan Chase & Co.Boost TargetNeutralGBX 132 ➝ GBX 174
7/29/2019UBS GroupBoost TargetNeutralGBX 120 ➝ GBX 129
7/29/2019Peel HuntReiterated RatingBuy
7/22/2019Peel HuntReiterated RatingBuy
7/12/2019Deutsche Bank AktiengesellschaftReiterated RatingSell
7/11/2019Peel HuntReiterated RatingBuy
7/3/2019Peel HuntReiterated RatingBuy
6/4/2019Peel HuntReiterated RatingBuy
5/9/2019JPMorgan Chase & Co.Reiterated RatingNeutralGBX 135 ➝ GBX 132
5/3/2019Jefferies Financial GroupReiterated RatingBuyGBX 145
5/3/2019Numis SecuritiesReiterated RatingBuyGBX 200
5/2/2019Deutsche Bank AktiengesellschaftLower TargetSellGBX 130 ➝ GBX 113
5/2/2019Peel HuntReiterated RatingBuy
4/30/2019CitigroupInitiated CoverageNeutralGBX 138
4/17/2019BarclaysReiterated RatingEqual WeightGBX 148 ➝ GBX 130
4/2/2019Peel HuntReiterated RatingBuy
3/25/2019Peel HuntUpgradeBuyGBX 150 ➝ GBX 230
3/12/2019Peel HuntReiterated RatingHold
2/19/2019The Goldman Sachs GroupLower TargetNeutralGBX 160 ➝ GBX 118
2/19/2019UBS GroupLower TargetNeutralGBX 150 ➝ GBX 120
2/18/2019JPMorgan Chase & Co.Reiterated RatingNeutralGBX 192 ➝ GBX 135
2/14/2019Peel HuntReiterated RatingHoldGBX 170 ➝ GBX 150
2/8/2019BarclaysLower TargetUnderweightGBX 150 ➝ GBX 148
2/1/2019Peel HuntReiterated RatingHold
1/21/2019Numis SecuritiesReiterated RatingBuyGBX 220
1/18/2019The Goldman Sachs GroupLower TargetNeutralGBX 165 ➝ GBX 160
1/4/2019Peel HuntReiterated RatingHold
1/2/2019JPMorgan Chase & Co.Reiterated RatingNeutral
12/10/2018Deutsche Bank AktiengesellschaftLower TargetSellGBX 180 ➝ GBX 130
12/6/2018Peel HuntReiterated RatingHold
11/27/2018BarclaysInitiated CoverageUnderweightGBX 150
11/1/2018Peel HuntReiterated RatingHold
10/31/2018Jefferies Financial GroupLower TargetBuyGBX 280 ➝ GBX 210
10/26/2018UBS GroupDowngradeNeutralGBX 250 ➝ GBX 150
10/25/2018Peel HuntLower TargetHoldGBX 220 ➝ GBX 170
10/16/2018JPMorgan Chase & Co.DowngradeNeutralGBX 280 ➝ GBX 183
10/15/2018Royal Bank of CanadaLower TargetOutperformGBX 240 ➝ GBX 210
10/15/2018Numis SecuritiesReiterated RatingHoldGBX 220
10/15/2018Peel HuntReiterated RatingHold
10/5/2018Deutsche Bank AktiengesellschaftReiterated RatingSell
10/3/2018Peel HuntReiterated RatingHold
9/4/2018Peel HuntReiterated RatingHold
8/8/2018Royal Bank of CanadaReiterated RatingOutperformGBX 240
8/3/2018Deutsche Bank AktiengesellschaftReiterated RatingSell
8/2/2018Numis SecuritiesReiterated RatingHold
8/1/2018Peel HuntReiterated RatingHoldGBX 210 ➝ GBX 220
7/4/2018Deutsche Bank AktiengesellschaftReiterated RatingSell
7/3/2018Peel HuntReiterated RatingHold
5/3/2018Credit Suisse GroupBoost TargetNeutralGBX 215 ➝ GBX 225
5/3/2018Deutsche Bank AktiengesellschaftReiterated RatingSell
5/2/2018Numis SecuritiesReiterated RatingHoldGBX 180
5/2/2018Peel HuntReiterated RatingHoldGBX 210
4/25/2018Credit Suisse GroupReiterated RatingNeutralGBX 215
4/24/2018Deutsche Bank AktiengesellschaftReiterated RatingSell
4/4/2018Peel HuntReiterated RatingHold
3/26/2018HSBCUpgradeBuyGBX 240 ➝ GBX 238
3/22/2018Royal Bank of CanadaUpgradeOutperformGBX 260 ➝ GBX 240
3/2/2018Peel HuntReiterated RatingHoldGBX 210
3/2/2018Numis SecuritiesReiterated RatingHoldGBX 180
2/23/2018Morgan StanleyReiterated RatingOverweightGBX 249
2/16/2018CitigroupReiterated RatingNeutralGBX 226
2/15/2018Credit Suisse GroupLower TargetNeutralGBX 225 ➝ GBX 215
2/15/2018Peel HuntReiterated RatingHoldGBX 250
2/15/2018Numis SecuritiesReiterated RatingHoldGBX 180
2/7/2018Numis SecuritiesUpgradeHoldGBX 180
2/1/2018Peel HuntReiterated RatingHoldGBX 250
12/5/2017Numis SecuritiesReiterated RatingReduceGBX 180
12/1/2017Deutsche Bank AktiengesellschaftReiterated RatingSellGBX 180
10/31/2017Peel HuntReiterated RatingHoldGBX 250
10/18/2017Numis SecuritiesUpgradeReduceGBX 180
10/17/2017Credit Suisse GroupLower TargetNeutralGBX 280 ➝ GBX 225
10/17/2017Peel HuntDowngradeHoldGBX 390 ➝ GBX 250
10/17/2017CitigroupLower TargetNeutralGBX 290 ➝ GBX 226
10/16/2017Numis SecuritiesDowngradeSellGBX 220
10/11/2017CitigroupReiterated RatingNeutralGBX 290
(Data available from 10/2/2017 forward)

News Sentiment Rating

0.61 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/6/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/5/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/5/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/4/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/4/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/3/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/2/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/2/2022

Current Sentiment

  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
ConvaTec Group logo
ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products used in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospital and home healthcare markets. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.
Read More

Today's Range

Now: GBX 205.60
Low: 201
High: 205.80

50 Day Range

MA: GBX 224.83
Low: 200.39
High: 245.80

52 Week Range

Now: GBX 205.60
Low: 165.30
High: 256

Volume

5,907,306 shs

Average Volume

4,029,497 shs

Market Capitalization

£4.20 billion

P/E Ratio

5,140.00

Dividend Yield

2.28%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of ConvaTec Group?

The following equities research analysts have issued reports on ConvaTec Group in the last year: Barclays PLC, Berenberg Bank, Citigroup Inc., JPMorgan Chase & Co., Royal Bank of Canada, and Shore Capital.
View the latest analyst ratings for CTEC.

What is the current price target for ConvaTec Group?

5 Wall Street analysts have set twelve-month price targets for ConvaTec Group in the last year. Their average twelve-month price target is GBX 259, suggesting a possible upside of 26.0%. Barclays PLC has the highest price target set, predicting CTEC will reach GBX 295 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of GBX 210 for ConvaTec Group in the next year.
View the latest price targets for CTEC.

What is the current consensus analyst rating for ConvaTec Group?

ConvaTec Group currently has 2 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CTEC will outperform the market and that investors should add to their positions of ConvaTec Group.
View the latest ratings for CTEC.

What other companies compete with ConvaTec Group?

How do I contact ConvaTec Group's investor relations team?

ConvaTec Group's physical mailing address is 3 Forbury Place Floor 7, 23 Forbury Road, ICKENHAM, RG1 3JH, United Kingdom. The company's listed phone number is 44 11 8952 8100. The official website for ConvaTec Group is www.convatecgroup.com. Learn More about contacing ConvaTec Group investor relations.